Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib Rollover Study in Advanced/Metastatic Cancer
NCT06506955Phase 3Active, not recruiting
- Sponsor
- Taiho Oncology
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 3 trial of futibatinib in cancer, metastatic cancer, sponsored by Taiho Oncology. Started Oct 2024; status: active, not recruiting.
02
Drugs
futibatinib
03
Conditions
cancermetastatic cancer
Beyond the preview
Go deeper on NCT06506955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506955.